Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 522 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Viread Clear all

Conditions: HIV Infections
Interventions: Placebo tablets; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,578 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more

Conditions: HIV-1 Infection
Interventions: Teropavimab, Zinlirvimab, Lenacapavir Tablet, Lenacapavir Injection, Antiretroviral Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 25 more

Conditions: Chronic Hepatitis B
Interventions: RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1 Infection
Interventions: Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, E/C/F/TAF Placebo, E/C/F/TAF, E/C/F/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 30 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more

Conditions: HIV-1/HBV Co-Infection
Interventions: B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more

Conditions: HIV Infections
Interventions: Tenofovir, Abacavir; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 5
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 2 more

Conditions: HIV Infections
Interventions: Tenofovir gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: HIV Prevention
Interventions: Descovy; Drug
Lead sponsor: Vivent Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin

Conditions: Chronic Hepatitis B
Interventions: Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV-1 Infection
Interventions: BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 12 more

Conditions: HIV
Interventions: Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: HIV Infection
Interventions: Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 94
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more

Conditions: HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 11 more

Conditions: HIV-1 Infections
Interventions: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Chicago, Illinois

Conditions: HIV/AIDS, Gender, Behavior and Behavior Mechanisms
Interventions: TDF/FTC; Drug
Lead sponsor: Hektoen Institute for Medical Research; Other
Eligibility: 15 Years to 24 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Immunodeficiency Virus Type 1
Interventions: D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 38
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more

Conditions: HIV Infections
Interventions: Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 54
States / cities: Hobson City, Alabama • Phoenix, Arizona • Beverly Hills, California + 50 more

Conditions: HIV Infections
Interventions: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT), NNRTIs (EFV, NVP), PIs (AMP, IDV, LPV/r, NFV, SQV, RTV); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 30 Days to 18 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 29
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 22 more

Conditions: HIV
Interventions: atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Search by objective public record fields.

B/F/TAF Ease of Swallowability Trial

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients

Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.